AKT1 and cancer: Among 62 patients with stage IIIB and IV cancer, a sufficient number of AKT–DC (> 7 × 109) needed for a course of treatment could not be obtained because of immunosuppression in 35 cases (56.5%), and these patients were excluded from the study.